Coronavirus

Moderna's cash hits $15B, new vaccine details released

Moderna has started submitting data for the evaluation of a third booster dose at the 50 µg dose level to both the Food and Drug Administration and the European Medicines Agency. The booster dose has been found to produce "robust antibody responses" in a phase 2 study.